Drug Trial Radar · NCT00445679
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
Last checked: Nov 19, 2026Latest source record: Nov 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
807
Actual
Start
Jul 2007
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
Conditions
- Depressive Disorder, Major
Interventions
DVS SRDrug
Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
ParoxetineDrug
20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)Time frame: 8 weeks
Locations
43 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Guangdong Province, China
Site not named
Hunan Province, China
Site not named
Jiangsu Province, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanxi Province, China
Site not named
Sichuan Province, China
Site not named
Yunnan Province, China
Site not named
Zhejiang Province, China
Site not named
Andhra Pradesh, India
Site not named
Andhra Pradesh, India
Site not named
Andhra Pradesh, India
Site not named
Andhra Pradesh, India
Site not named
Chandigarh, India
Site not named
Gujarat, India
Site not named
Gujarat, India
Site not named
Karnataka, India
Site not named
Karnataka, India
Site not named
Maharashtra, India
Site not named
Maharashtra, India
Site not named
Maharashtra, India
Site not named
Mumbai Maharashtra, India
Site not named
New Delhi, India
Site not named
Punjab, India
Site not named
Uttar Pradesh, India
Site not named
Incheon, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Seoul, South Korea
Site not named
Chang-hua, Taiwan
Site not named
Kaohsiung City, Taiwan
Site not named
Taipei, Taiwan
Site not named
Taipei, Taiwan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.